Jeffrey A Boerth, Alex J Chinn, Marianne Schimpl, Gayathri Bommakanti, Christina Chan, Erin L Code, Kathryn A Giblin, Andrea Gohlke, Catherine S Hansel, Meizhong Jin, Stefan L Kavanagh, Michelle L Lamb, Jordan S Lane, Carrie J B Larner, Adelphe M Mfuh, Rachel K Moore, Taranee Puri, Taylor R Quinn, Minwei Ye, Kevin J Robbins, Miguel Gancedo-Rodrigo, Haoran Tang, Jarrod Walsh, Jamie Ware, Gail L Wrigley, Iswarya Karapa Reddy, Yun Zhang, Neil P Grimster
Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) is a RING finger E3 ligase that is responsible for repressing T-cell, natural killer (NK) cell, and B-cell activation. The robust antitumor activity observed in Cbl-b deficient mice arising from elevated T-cell and NK-cell activity justified our discovery effort toward Cbl-b inhibitors that might show therapeutic promise in immuno-oncology, where activation of the immune system can drive the recognition and killing of cancer cells. We undertook a high-throughput screening campaign followed by structure-enabled optimization to develop a novel benzodiazepine series of potent Cbl-b inhibitors...
December 14, 2023: ACS Medicinal Chemistry Letters